Glycosylated ferritin testing for adult Still's disease and macrophage activation syndrome
Official title: Glycosylated Ferritin in Differential Diagnosis of Still's Disease, Sepsis and Other Macrophagic Activation Syndromes.
Run by Brugmann University Hospital · NCT02143986 · Data updated 2026-11-12
This study will test whether measuring the glycosylated portion of ferritin helps diagnose adult-onset Still's disease and macrophage activation syndrome in adults with high ferritin or suspected sepsis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 85 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Brugmann University Hospital Academic / other |
| Locations | 1 site (Brussels) |
| Status | Recruiting |
| Started | May 2014 |
| Main results expected | December 2030 |
| Study ends | December 2030 |
| Registry record updated | October 6, 2025 |
| Trial ID | NCT02143986 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with suspected macrophage activation syndrome/HLH, adult-onset Still's disease, unexplained hyperferritinemia, or clinical suspicion of severe sepsis are ideal candidates.
✕Probably not a fit
Patients with normal ferritin levels or those whose ferritin glycosylation is altered by unrelated conditions (for example severe liver disease or certain malignancies) may not benefit from this test.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study collecting serum from adults with suspected HLH/macrophage activation syndrome or adult-onset Still's disease and from control groups with sepsis, autoimmune inflammation, hepatic necrosis, or hematologic malignancy. The study measures the percentage of glycosylated ferritin and characterizes ferritin glycoforms, including mass spectrometry analysis. Investigators will compare glycosylated ferritin levels and glycoform patterns between diagnostic groups to determine diagnostic performance. Results will be correlated with clinical and laboratory diagnostic criteria recorded by treating physicians.
Why it matters
Potential benefit: If successful, the test could help doctors more accurately distinguish HLH or adult Still's disease from other causes of very high ferritin, enabling faster, more targeted care.
How similar studies have gone: Prior reports have found glycosylated ferritin below 20% in adult Still's disease and HLH and the marker appears in some diagnostic criteria, but it has limitations and is not yet fully validated across diverse control conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Suspicion of sepsis, macrophagic activation syndrome, Still's disease or hyperferritinemia (malignant disease, hepatic cytolysis) Exclusion Criteria: * Normal ferritin level
Where it's running
-
Brugmann University Hospital
Brussels, Belgium Recruiting
Study contacts
- Study coordinator: Francis Corazza, MD, PhD
- Email: francis.corazza@ulb.ac.be
- Phone: 32-2-4772506
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care
This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.
-
Early detection of sepsis-related blood clotting problems in severe burn patients
This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.
-
Neutrophil EMR3 as a biomarker for sepsis in ICU patients
Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.
-
Thymalfasin added to standard care for adults with sepsis and immune dysfunction
This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.
-
Multicenter group study of sepsis and ARDS in China
This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.